Leading Fully Human Antibody
and AI-Driven Innovation
and AI-Driven Innovation
Leveraging our proprietary Harbour Mice® platform and AI generation models, we rapidly address unmet medical needs globally.
Our proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. The HCAb-based Antibody Plus technology (HCAb PLUS™) provides comprehensive modality solutions for the development of innovative multi-specific medicines in different disease areas. Additionally, building upon the Harbour Mice® platform, Harbour BioMed launched its first fully human Generative AI HCAb Model powered by its Hu-mAtrIx™AI platform, accelerating the development of innovative therapies.
By integrating Harbour Mice®, HBICE®, HCAb PLUS™, a single B-cell cloning platform and AI technologies, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies.
Our proprietary fully human transgenic mouse platform generates fully human, affinity-matured classical antibodies (H2L2) and heavy chain-only antibodies (HCAb) with excellent developability.
Utilizing state-of-the-art Beacon optofluidic technology, we have established a full process for single B cell cloning, significantly increasing the efficiency and productivity of antibody drug discovery.
Based on the heavy chain-only antibodies generated from the HCAb Harbour Mice® platform, we have established the proprietary HBICE® (HCAb-Based Immune Cell Engagers) platform to rapidly develop bispecific/multi-specific antibodies that redirect immune cells to the tumor microenvironment (TME) for tumor eradication.
Built on the Harbour Mice® platform, Harbour BioMed launched the world' s first fully human Generative AI HCAb (Heavy Chain-Only Antibody) Model, accelerating the development of innovative therapies.
